(Reuters) – The $26,500-per-year price tag for Eisai Co Ltd and Biogen Inc’s newly approved Alzheimer’s disease drug is slightly above expectations, but should not dent demand for the promising…
(Reuters) – Japanese drugmaker Eisai Co Ltd said on Saturday it had submitted an application to the U.S. Food and Drug Administration for a standard review of its Alzheimer’s drug…
(Reuters) – The U.S. Food and Drug Administration on Friday approved Eisai Co Ltd and Biogen Inc’s Alzheimer’s drug lecanemab for the treatment of early forms of the fatal, brain-wasting…
By Deena Beasley and Julie Steenhuysen SAN FRANCISCO (Reuters) – Japan’s Eisai Co plans to seek full approval of its experimental Alzheimer’s drug lecanemab in the United States, Europe and…
Biogen, and its Japanese partner Eisai, announced Monday that it plans to begin the process for U.S. approval for its experimental drug for Alzheimer’s. Biogen and Eisai announced “rolling submission”…